Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells

Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells

Abstract Background For most patients, pancreatic adenocarcinoma responds poorly to treatment, and novel therapeutic approaches are needed. Standard-of-care paclitaxel (PTX), combined with birinapant (BRP), a bivalent mimetic of the apoptosis antagonist SMAC (second mitochondria-derived activator of...

Full description

Bibliographic Details
Main Authors: Jin Niu, Xue Wang, Jun Qu, Donald E. Mager, Robert M. Straubinger
Format: Article
Language:English
Published: BMC 2020-10-01
Series:BMC Cancer
Subjects:
Pharmacodynamic interaction
Synergy
Mathematical modeling
Birinapant
Paclitaxel
Online Access:http://link.springer.com/article/10.1186/s12885-020-07398-9

Internet

http://link.springer.com/article/10.1186/s12885-020-07398-9

Similar Items